Our top pick for
Building a portfolio
Cocrystal Pharma, Inc is a biotechnology business based in the US. Cocrystal Pharma shares (COCP) are listed on the NASDAQ and all prices are listed in US Dollars. Cocrystal Pharma employs 11 staff and has a trailing 12-month revenue of around USD$1.9 million.
|Latest market close||USD$1.54|
|52-week range||USD$0.45 - USD$2.48|
|50-day moving average||USD$1.3518|
|200-day moving average||USD$1.3399|
|Wall St. target price||USD$4.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.467|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||0.65%|
|1 month (2020-12-22)||1.99%|
|3 months (2020-10-21)||75.00%|
|6 months (2020-07-21)||-24.51%|
|1 year (2020-01-21)||105.88%|
|2 years (2019-01-18)||-60.10%|
|3 years (2018-01-19)||719.58%|
|5 years (2016-01-21)||190.57%|
|Revenue TTM||USD$1.9 million|
|Gross profit TTM||USD$2.6 million|
|Return on assets TTM||-9.81%|
|Return on equity TTM||-92.62%|
|Market capitalisation||USD$106.3 million|
TTM: trailing 12 months
There are currently 851,508 Cocrystal Pharma shares held short by investors – that's known as Cocrystal Pharma's "short interest". This figure is 53.3% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Cocrystal Pharma shares can be evaluated.
Cocrystal Pharma's "short interest ratio" (SIR) is the quantity of Cocrystal Pharma shares currently shorted divided by the average quantity of Cocrystal Pharma shares traded daily (recently around 8.5 million). Cocrystal Pharma's SIR currently stands at 0.1. In other words for every 100,000 Cocrystal Pharma shares traded daily on the market, roughly 100 shares are currently held short.
However Cocrystal Pharma's short interest can also be evaluated against the total number of Cocrystal Pharma shares, or, against the total number of tradable Cocrystal Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cocrystal Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cocrystal Pharma shares in existence, roughly 10 shares are currently held short) or 0.016% of the tradable shares (for every 100,000 tradable Cocrystal Pharma shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cocrystal Pharma.
Find out more about how you can short Cocrystal Pharma stock.
We're not expecting Cocrystal Pharma to pay a dividend over the next 12 months.
Cocrystal Pharma's shares were split on a 1:30 basis on 24 January 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cocrystal Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cocrystal Pharma shares which in turn could have impacted Cocrystal Pharma's share price.
Over the last 12 months, Cocrystal Pharma's shares have ranged in value from as little as $0.45 up to $2.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cocrystal Pharma's is 1.1654. This would suggest that Cocrystal Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.